دورية أكاديمية
أعرض في EDS

Increasing levels of the endocannabinoid 2-AG is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.

التفاصيل البيبلوغرافية
العنوان: Increasing levels of the endocannabinoid 2-AG is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
المؤلفون: Mounsey RB; Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, AB25 2ZD Scotland, UK., Mustafa S; Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, AB25 2ZD Scotland, UK., Robinson L; Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, AB25 2ZD Scotland, UK; Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY Scotland, UK., Ross RA; Department of Pharmacology and Toxicology, University of Toronto, Medical Sciences Building, 1 King's College Circle, Toronto, Ontario M5S 1A, Canada., Riedel G; Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, AB25 2ZD Scotland, UK., Pertwee RG; Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, AB25 2ZD Scotland, UK., Teismann P; Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, AB25 2ZD Scotland, UK. Electronic address: p.teismann@abdn.ac.uk.
المصدر: Experimental neurology [Exp Neurol] 2015 Nov; Vol. 273, pp. 36-44. Date of Electronic Publication: 2015 Aug 02.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Academic Press Country of Publication: United States NLM ID: 0370712 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1090-2430 (Electronic) Linking ISSN: 00144886 NLM ISO Abbreviation: Exp Neurol Subsets: MEDLINE
أسماء مطبوعة: Publication: Orlando Fl : Academic Press
Original Publication: New York.
مواضيع طبية MeSH: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine*/pharmacology, Arachidonic Acids/*therapeutic use , Endocannabinoids/*therapeutic use , Glycerides/*therapeutic use , Neuroprotective Agents/*therapeutic use , Neurotoxins/*toxicity , Parkinson Disease/*diet therapy , Parkinson Disease/*etiology, Animals ; Benzodioxoles/therapeutic use ; Brain/drug effects ; Brain/metabolism ; Brain/pathology ; Cell Death/drug effects ; Cyclooxygenase 2/metabolism ; Disease Models, Animal ; Dose-Response Relationship, Drug ; Enzyme Inhibitors/pharmacology ; Furans/therapeutic use ; Gait Disorders, Neurologic/drug therapy ; Gait Disorders, Neurologic/etiology ; Male ; Mice ; Mice, Inbred C57BL ; Motor Activity/drug effects ; Parkinson Disease/complications ; Parkinson Disease/pathology ; Piperidines/therapeutic use ; Time Factors ; Tyrosine 3-Monooxygenase/metabolism
مستخلص: Parkinson's disease (PD) is a common chronic neurodegenerative disorder, usually of idiopathic origin. Symptoms including tremor, bradykinesia, rigidity and postural instability are caused by the progressive loss of dopaminergic neurons in the nigrostriatal region of the brain. Symptomatic therapies are available but no treatment slows or prevents the loss of neurons. Neuroinflammation has been implicated in its pathogenesis. To this end, the present study utilises the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxin to reproduce the pattern of cell death evident in PD patients. Herein, the role of a potential regulator of an immune response, the endocannabinoid system (ECS), is investigated. The most prevalent endocannabinoid, 2-arachidonoylglycerol (2-AG) (3 and 5mg/kg), was added exogenously and its enzymatic degradation inhibited to provide protection against MPTP-induced cell death. Furthermore, the addition of DFU (25mg/kg), a selective inhibitor of inflammatory mediator cyclooxygenase-2 (COX-2), potentiated these effects. Levels of 2-AG were shown to be upregulated in a time- and region-specific manner following MPTP administration, indicating that the ECS represents a natural defence mechanism against inflammation, potentiation of which could provide therapeutic benefits. The results expand the current understanding of the role that this signalling system has and its potential influence in PD.
(Copyright © 2015. Published by Elsevier Inc.)
References: Neurosci Lett. 1995 Dec 29;202(1-2):17-20. (PMID: 8787820)
Br J Pharmacol. 2011 Aug;163(7):1533-49. (PMID: 21501147)
Ann Neurol. 2004 Jul;56(1):51-60. (PMID: 15236401)
Nature. 2001 Oct 4;413(6855):527-31. (PMID: 11586361)
Br J Pharmacol. 2007 Jan;150(2):186-91. (PMID: 17143303)
Mol Neurobiol. 2007 Aug;36(1):82-91. (PMID: 17952653)
Br J Pharmacol. 2010 Jun;160(3):467-79. (PMID: 20590558)
Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10819-24. (PMID: 12136125)
Nat Chem Biol. 2009 Jan;5(1):37-44. (PMID: 19029917)
Chem Biol. 2007 Dec;14(12):1347-56. (PMID: 18096503)
Brain. 2011 Jan;134(Pt 1):119-36. (PMID: 20929960)
Cell Death Differ. 2015 Oct;22(10):1618-29. (PMID: 25698444)
J Biol Chem. 2008 Aug 15;283(33):22601-11. (PMID: 18534982)
Eur J Neurosci. 2009 Jun;29(11):2177-86. (PMID: 19490092)
Science. 2011 Nov 11;334(6057):809-13. (PMID: 22021672)
Neurobiol Dis. 2005 Jun-Jul;19(1-2):96-107. (PMID: 15837565)
Glia. 2009 Feb;57(3):286-94. (PMID: 18837048)
J Neurosci. 2005 Feb 23;25(8):1904-13. (PMID: 15728830)
Biochem Biophys Res Commun. 1999 Mar 16;256(2):377-80. (PMID: 10079192)
Brain. 2009 Nov;132(Pt 11):3152-64. (PMID: 19805493)
Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20270-5. (PMID: 19918051)
J Biol Chem. 2000 Oct 27;275(43):33744-9. (PMID: 10931854)
Behav Brain Res. 2009 Nov 5;203(2):304-7. (PMID: 19414037)
Br J Pharmacol. 1997 May;121(1):105-17. (PMID: 9146894)
Neurosci Lett. 1994 Jan 3;165(1-2):208-10. (PMID: 8015728)
Nat Neurosci. 2010 Sep;13(9):1113-9. (PMID: 20729846)
J Mol Med (Berl). 2007 Dec;85(12):1379-92. (PMID: 17639288)
Int J Biochem Cell Biol. 2005 Aug;37(8):1620-5. (PMID: 15896668)
Mol Neurobiol. 2016 May;53(4):2312-9. (PMID: 25976369)
J Neurochem. 2000 May;74(5):2213-6. (PMID: 10800968)
Neurobiol Dis. 2006 Oct;24(1):15-27. (PMID: 16762556)
J Neurosci. 2014 Nov 5;34(45):14919-33. (PMID: 25378159)
J Cereb Blood Flow Metab. 2005 Apr;25(4):477-84. (PMID: 15729296)
Nat Med. 1999 Dec;5(12):1403-9. (PMID: 10581083)
Chem Biol. 2007 Dec;14(12):1357-65. (PMID: 18096504)
J Pharmacol Exp Ther. 2009 Nov;331(2):591-7. (PMID: 19666749)
Br J Pharmacol. 2011 Aug;163(7):1495-506. (PMID: 21323909)
FASEB J. 2006 May;20(7):1003-5. (PMID: 16571781)
Neuroscience. 2011 Mar 31;178:159-68. (PMID: 21256197)
AAPS J. 2006;8(2):E298-306. (PMID: 16796380)
Acta Neurol Scand. 1998 Aug;98(2):142-4. (PMID: 9724016)
Neuroscience. 2010 Sep 29;170(1):324-36. (PMID: 20600638)
Nat Protoc. 2007;2(1):141-51. (PMID: 17401348)
Neurosci Lett. 1994 Oct 24;180(2):147-50. (PMID: 7700568)
Neurology. 1988 Aug;38(8):1285-91. (PMID: 3399080)
J Neurochem. 2003 Mar;84(5):1097-109. (PMID: 12603833)
Proc Natl Acad Sci U S A. 2014 Jun 3;111(22):8257-62. (PMID: 24843137)
Br J Pharmacol. 2010 Jun;160(3):657-68. (PMID: 20590569)
Cell Death Dis. 2013;4:e862. (PMID: 24136226)
Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5473-8. (PMID: 12702778)
Brain. 2012 Nov;135(Pt 11):3336-47. (PMID: 23169921)
J Med Chem. 2010 Feb 25;53(4):1830-42. (PMID: 20099888)
Nature. 2005 Jun 23;435(7045):1108-12. (PMID: 15973410)
Br J Pharmacol. 2007 Nov;152(5):787-94. (PMID: 17700715)
J Microsc. 1987 Sep;147(Pt 3):229-63. (PMID: 3430576)
Cell Mol Life Sci. 2006 Jun;63(12):1410-24. (PMID: 16732431)
Lancet Neurol. 2006 Jun;5(6):525-35. (PMID: 16713924)
Neurobiol Aging. 1993 Jul-Aug;14(4):275-85. (PMID: 8367009)
Neuron. 2003 Sep 11;39(6):889-909. (PMID: 12971891)
Neurobiol Aging. 2014 Nov;35(11):2603-16. (PMID: 24973119)
معلومات مُعتمدة: WT080782MF United Kingdom Wellcome Trust
فهرسة مساهمة: Keywords: Endocannabinoids; MPTP; Neuroprotection; Parkinson's disease
المشرفين على المادة: 0 (5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone)
0 (Arachidonic Acids)
0 (Benzodioxoles)
0 (Endocannabinoids)
0 (Enzyme Inhibitors)
0 (Furans)
0 (Glycerides)
0 (JZL 184)
0 (Neuroprotective Agents)
0 (Neurotoxins)
0 (Piperidines)
8D239QDW64 (glyceryl 2-arachidonate)
9P21XSP91P (1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine)
EC 1.14.16.2 (Tyrosine 3-Monooxygenase)
EC 1.14.99.1 (Cyclooxygenase 2)
تواريخ الأحداث: Date Created: 20150806 Date Completed: 20160218 Latest Revision: 20181113
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC4654430
DOI: 10.1016/j.expneurol.2015.07.024
PMID: 26244281
قاعدة البيانات: MEDLINE
الوصف
تدمد:1090-2430
DOI:10.1016/j.expneurol.2015.07.024